Abstract IA006: Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi- Selective Inhibitors in NRAS-Mutated Melanoma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaOriginal Research · 2026 · 2 citations
2. 2Abstract A028: Non-genetic resistance to multi-selective RAS(ON) inhibitors in NRAS-mutant melanomaOriginal Research · 2026
3. 3Abstract 1884: Molecular determinants of sensitivity and resistance to the pan-RAS(ON) inhibitor daraxonrasib(RMC-6236) across KRAS-mutant patient-derived models.Original Research · 2026
4. 4Abstract B046: Pan-RAS Inhibition as a novel therapeutic strategy for RAS-driven rhabdomyosarcomaOriginal Research · 2026
5. 5Abstract 1217: Defining the anti-tumor activity and immune effects of the RASMULTI(ON) inhibitor RMC-7977 in preclinical models of NRAS-mutant melanoma2024